Back to Search Start Over

Lactococcus lactis as a vehicle for the heterologous expression of fungal ribotoxin variants with reduced IgE-binding affinity.

Authors :
Alvarez-García E
Alegre-Cebollada J
Batanero E
Monedero V
Pérez-Martínez G
García-Fernández R
Gavilanes JG
del Pozo AM
Source :
Journal of biotechnology [J Biotechnol] 2008 Mar 20; Vol. 134 (1-2), pp. 1-8. Date of Electronic Publication: 2008 Jan 18.
Publication Year :
2008

Abstract

Fungal ribotoxins are a family of extracellular ribonucleases which inhibit protein biosynthesis by inactivating the ribosomes. This inactivation results in the induction of cell death by apoptosis. Ribotoxins show antitumoral properties based on their ability to cross the membrane of some transformed cells. Unfortunately, they also show an unspecific cytotoxicity which has greatly impaired their potential clinical uses. alpha-Sarcin, produced by Aspergillus giganteus, is the best-characterized ribotoxin. Asp f 1, another ribotoxin produced by A. fumigatus, is indeed one of its major allergens. In this work, the Lactococcus lactis MG1363 strain has been engineered to produce and secrete not only wild-type Asp f 1 and alpha-sarcin but also three different mutants with reduced cytotoxicity and/or IgE-binding affinity. The proteins were secreted in native and active form when the extracellular medium employed was buffered at pH values around 8.0. Strains producing the wild-type natural alpha-sarcin were proved to be innocuous when administered intragastrically to mice for a period of 14 days. Overall, the results presented are discussed in terms of its potential application as a vehicle of oral delivery of hypoallergenic variants as well as a starting point to approach the design of strategies to accomplish the safe delivery of these proteins as antitumoral agents.

Details

Language :
English
ISSN :
0168-1656
Volume :
134
Issue :
1-2
Database :
MEDLINE
Journal :
Journal of biotechnology
Publication Type :
Academic Journal
Accession number :
18289711
Full Text :
https://doi.org/10.1016/j.jbiotec.2007.12.011